???Chickens Coming Home To Roost: Part III


Meanwhile, Pfizer said it would halt enrollment in a trial for its Covid-19 antiviral drug, Paxlovid, in standard-risk patients after a study revealed the treatment was not effective in reducing symptoms in that group.

It will include the new data in the company’s upcoming application to the U.S. Food and Drug Administration seeking full approval for the drug’s use in high-risk groups.

Data from a study in Israel earlier this month showed the drug reduces Covid-19 hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older, but was not found to prevent severe illness among younger adults.

More than 1.2 million courses of Paxlovid have been administered in the United States, according to data from the Assistant Secretary for Preparedness and Response under the U.S. Department of Health & Human Services.

You are more likely to have an adverse reaction than gain protection from the ?Watch this interview and UNDERSTAND what happened

‘Everything we had to go on at the beginning was based upon that figure which was exaggerated in terms of its benefits… the information has evolved since then, considerably.’

Dr Aseem Malhotra spoke to Mark Steyn about why he’s calling for greater vaccine data transparency. This is an incredible interview. (In full below).

Did you know this? “For every 119 individuals vaccinated, one person would be protected from the infection!” Your risk of an adverse reaction is greater than your chance of being protected.

And those poor babies…

Too little, too late